You Are Here:
This review of the evidence was funded by the Agency for Healthcare Research and Quality (AHRQ) for the U.S. Preventive Services Task Force (USPSTF). The investigators acknowledge the contributions of Kim Villemyer for her help in preparing the full evidence report and the manuscript; Christina Bougatsos for her help in preparing the manuscript; and Andrew Hamilton, M.L.S., M.S., for conducting the literature searches. They also thank Mark Helfand, M.D., M.P.H.; Heidi D. Nelson, M.D., M.P.H.; David Lanier, M.D.; members of the U.S. Preventive Services Task Force; and reviewers for their contributions to this project.
This study was conducted by the Oregon Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ). Contract No. 290-02-0024, Rockville, MD.
1. Fleming P, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV prevalence in the United States, 2000 [Abstract]. In: Program and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 24-28 February 2002. Alexandria, Virginia: Foundation for Retrovirology and Human Health; 2002.
8. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362:679-86.
13. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: U.S. Department of Health and Human Services; 7 April 2005. Accessed at www.aidsinfo.nih.gov/guidelines/adult/aa_040705.pdf.
14. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society—USA Panel. JAMA 2004;292:251-65.
16. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:1-52.
17. Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT. Screening for human immunodeficiency virus in adolescents and adults: systematic evidence synthesis. Rockville, MD: Agency for Healthcare Research and Quality; 2005. Available at http://www.uspreventiveservicestaskforce.org/uspstfix.htm.
19. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, et al. The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001;20:36-43.
22. Murphy DA, Durako SJ, Moscicki AB, Vermund SH, Ma Y, Schwarz DF, et al. No change in health risk behaviors over time among HIV infected adolescents in care: role of psychological distress. J Adolesc Health 2001;29:57-63.
25. HIV Testing Survey, 2002. HIV/AIDS Special Surveillance Report 5. Atlanta: Centers for Disease Control and Prevention; 2004. Accessed at www.cdc.gov/hiv/stats/HIV-Test-Survey2002.pdf on 21 March 2005.
26. Klein D, Hurley LB, Merrill D, Quesenberry CP Jr. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003;32:143-52.
29. Groseclose SL, Erickson B, Quinn TC, Glasser D, Campbell CH, Hook EW 3rd. Characterization of patients accepting and refusing routine, voluntary HIV antibody testing in public sexually transmitted disease clinics. Sex Transm Dis 1994;21:31-5.
30. Erickson B, Wasserheit JN, Rompalo AM, Brathwaite W, Glasser D, Hook EW 3rd. Routine voluntary HIV screening in STD clinic clients: characterization of infected clients. Sex Transm Dis 1990;17:194-9.
38. Kirkland KB, Meriwether RA, MacKenzie WR, Binz WC, Allen RJ, Veenhuis PE. Clinician judgement as a tool for targeting HIV counseling and testing in North Carolina state mental hospitals, 1994. AIDS Patient Care STDS 1999;13:473-9.
39. Kelen GD, Hexter DA, Hansen KN, Humes R, Vigilance PN, Baskerville M, et al. Feasibility of an emergency department-based, risk-targeted voluntary HIV screening program. Ann Emerg Med 1996;27:687-92.
43. Goggin MA, Davidson AJ, Cantril SV, O'Keefe LK, Douglas JM. The extent of undiagnosed HIV infection among emergency department patients: results of a blinded seroprevalence survey and a pilot HIV testing program. J Emerg Med 2000;19:13-9.
47. MacDonald KL, Jackson JB, Bowman RJ, Polesky HF, Rhame FS, Balfour HH Jr, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med 1989;110:617-21.
48. Kleinman S, Busch MP, Hall L, Thomson R, Glynn S, Gallahan D, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA 1998;280:1080-5.
54. O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, Zahwa H, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003;41:2153-5.
55. Reynolds SJ, Ndongala LM, Luo CC, Mwandagalirwa K, Losoma AJ, Mwamba KJ, et al. Evaluation of a rapid test for the detection of antibodies to human immunodeficiency virus type 1 and 2 in the setting of multiple transmitted viral subtypes. Int J STD AIDS 2002;13:171-3.
57. Rapid HIV antibody testing during labor and delivery for women of unknown HIV status. Atlanta: Centers for Disease Control and Prevention; 30 January 2004. Accessed at www.cdc.gov/hiv/rapid_testing/materials/Labor&DeliveryRapidTesting.pdf on 20 July 2004.
58. Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl MS. Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. OraSure HIV Clinical Trials Group. JAMA 1997;277:254-8.
59. Granade TC, Phillips SK, Parekh B, Gomez P, Kitson-Piggott W, Oleander H, et al. Detection of antibodies to human immunodeficiency virus type 1 in oral fluids: a large-scale evaluation of immunoassay performance. Clin Diagn Lab Immunol 1998;5:171-5.
60. HIV assays: operational characteristics (phase I)— urine and oral fluid (saliva) specimens. Geneva, Switzerland: World Health Organization; January 2002. Available at www.who.int/diagnostics_laboratory/publications/en/hiv_assays_rep_13.pdf.
61. Martinez PM, Torres AR, Ortiz de Lejarazu R, Montoya A, Martin JF, Eiros JM. Human immunodeficiency virus antibody testing by enzyme-linked fluorescent and western blot assays using serum, gingival-crevicular transudate, and urine samples. J Clin Microbiol 1999;37:1100-6.
64. Frank AP, Wandell MG, Headings MD, Conant MA, Woody GE, Michel C. Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation. Arch Intern Med 1997;157:309-14.
65. Spielberg F, Critchlow C, Vittinghoff E, Coletti AS, Sheppard H, Mayer KH, et al. Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results. HIV Early Detection Study Group. AIDS 2000;14:1819-28.
67. Mylonakis E, Paliou M, Greenbough TC, Flaningan TP, Letvin NL, Rich JD. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med 2000;160:2386-8.
73. Kilmarx PH, Hamers FF, Peterman TA. Living with HIV. Experiences and perspectives of HIV-infected sexually transmitted disease clinic patients after posttest counseling. Sex Transm Dis 1998;25:28-37.
80. Perry S, Fishman B, Jacobsberg L, Young J, Frances A. Effectiveness of psychoeducational interventions in reducing emotional distress after human immunodeficiency virus antibody testing. Arch Gen Psychiatry 1991;48:143-7.
81. Chesney MA, Chambers DB, Taylor JM, Johnson LM, Folkman S. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med 2003;65:1038-46.
82. Antoni MH, Cruess DG, Cruess S, Lutgendorf S, Kumar M, Ironson G, et al. Cognitive-behavioral stress management intervention effects on anxiety, 24-hr urinary norepinephrine output, and T-cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men. J Consult Clin Psychol 2000;68:31-45.
83. Cruess DG, Antoni MH, Schneiderman N, Ironson G, McCabe P, Fernandez JB, et al. Cognitive-behavioral stress management increases free testosterone and decreases psychological distress in HIV-seropositive men. Health Psychol 2000;19:12-20.
86. Cohen M, Deamant C, Barkan S, Richardson J, Young M, Holman S, et al. Domestic violence and childhood sexual abuse in HIV-infected women and women at risk for HIV. Am J Public Health 2000;90:560-5.
87. Kissinger PJ, Niccolai LM, Magnus M, Farley TA, Maher JE, Richardson-Alston G, et al. Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis 2003;30:75-82.
93. Kellerman SE, Lehman JS, Lansky A, Stevens MR, Hecht FM, Bindman AB, et al. HIV testing within at-risk populations in the United States and the reasons for seeking or avoiding HIV testing. J Acquir Immune Defic Syndr 2002;31:202-10.
99. Bindman AB, Osmond D, Hecht FM, Lehman JS, Vranizan K, Keane D, et al. Multistate evaluation of anonymous HIV testing and access to medical care. Multistate Evaluation of Surveillance of HIV (MESH) Study Group. JAMA 1998;280:1416-20.
101. Nakashima AK, Horsley R, Frey RL, Sweeney PA, Weber JT, Fleming PL. Effect of HIV reporting by name on use of HIV testing in publicly funded counseling and testing programs. JAMA 1998;280:1421-6.
105. Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Combs CM, et al. HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment. J Acquir Immune Defic Syndr 2001;27:135-42.
108. Sy FS, Rhodes SD, Choi ST, Drociuk D, Laurent AA, Naccash RM, et al. The acceptability of oral fluid testing for HIV antibodies. A pilot study in gay bars in a predominantly rural state. Sex Transm Dis 1998;25:211-5.
109. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360:119-29.
115. Hutchinson CM, Wilson C, Reichart CA, Marsiglia VC, Zenilman JM, Hook EW 3rd. CD4 lymphocyte concentrations in patients with newly identified HIV infection attending STD clinics. Potential impact on publicly funded health care resources. JAMA 1991;266:253-6.
116. Dybul M, Bolan R, Condoluci D, Cox-Iyamu R, Redfield R, Hallahan CW, et al. Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis 2002;185:1818-21.
117. HIV counseling and testing in publicly funded sites. Annual Report 1997 and 1998. Atlanta: Centers for Disease Control and Prevention; 2001. Accessed at www.cdc.gov/hiv/pubs/cts98.pdf on 3 March 2005.
124. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med 1998;339:1897-904.
125. Turner BJ, Cunningham WE, Duan N, Andersen RM, Shapiro MF, Bozzette SA, et al. Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus. Arch Intern Med 2000;160:2614-22.
126. Supplement to HIV/AIDS surveillance (SHAS): demographics and behavioral data from a supplemental HIV/AIDS behavioral surveillance project 1997-2000. Special Surveillance Report No. 2. Atlanta: Centers for Disease Control and Prevention; 2004:1-27.
127. Osmond DH, Bindman AB, Vranizan K, Lehman JS, Hecht FM, Keane D, et al. Name-based surveillance and public health interventions for persons with HIV infection. Multistate Evaluation of Surveillance for HIV Study Group. Ann Intern Med 1999;131:775-9.
128. Samet JH, Freedberg KA, Stein MD, Lewis R, Savetsky J, Sullivan L, et al. Trillion virion delay: time from testing positive for HIV to presentation for primary care. Arch Intern Med 1998;158:734-40.
129. Stall R, Pollack L, Mills TC, Martin JN, Osmond D, Paul J, et al. Use of antiretroviral therapies among HIV-infected men who have sex with men: a household-based sample of 4 major American cities. Am J Public Health 2001;91:767-73.
130. Cunningham WE, Markson LE, Andersen RM, Crystal SH, Fleishman JA, Golin C, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000;25:115-23.
131. Kaplan JE, Parham DL, Soto-Torres L, van Dyck K, Greaves JA, Rauch K, et al. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. J Acquir Immune Defic Syndr 1999;21:228-35.
134. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 2003;17:2345-9.
135. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003;163:2187-95.
136. Garcia F, De Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count. J Acquir Immune Defic Syndr 2004;36:702-13.
137. AIDS cases, deaths, and persons living with AIDS by year, 1985-2002—United States. Atlanta: Centers for Disease Control and Prevention; 2002. Accessed at http://www.cdc.gov/hiv/stats/hasr1402.htm on 2 December 2004.
138. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
139. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 1999;13:1687-95.